DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
Targeting Therapy Resistant Tumor Vessels
Final rept. 1 may 2006-31 Aug 2008
BURNHAM INST LA JOLLA CA
Pagination or Media Count:
Anti-angiogenic therapy appears to eliminate immature blood vessels. This paradoxically leads to improvement of tumor blood supply, as the structure and function of mature tumor blood vessels, not specific for anti-angiogenic effect, is normalized. This is a serious limitation to the anti-angiogenic therapy. The goal of this project is to specifically distinguish these normalized therapy resistant vessels in breast cancer from those sensitive to anti-angiogenic treatment. To achieve this, we have developed tumor models for vascular normalization and are using in vivo phage display and isolation of peptides that specifically home to normalized tumor vessels resistant to anti-angiogenic therapy. The results obtained in this study will enable specific targeting and thus treatment of breast cancer vessels not responding to standard anti-angiogenic therapy.
APPROVED FOR PUBLIC RELEASE